Learning to live with the “new normal” … or avoid it if you can

Very, very, very slowly it appears that we are starting to see some serious interest in research into the psychosocial impact of prostate cancer and its treatment on men and their close family members and/or intimate partners. … READ MORE …

How broadly is your doctor smiling?

Dr. Craig Hildreth is a medical oncologist who writes a regular blog about issues related to the management of patients with cancer on the CancerNetwork web site. … READ MORE …

Living with late stage prostate cancer

There is a valuable video interview that was put on line a couple of days ago featuring Dr. William Oh of the Mount Sinai Hospital and Medical School in New York and Jan Manarite of the Prostate Cancer Research Institute. … READ MORE …

Baseline data from the ProtecT trial … with outcomes still to come

Many readers of this blog will be interested to look through the data on the preliminary study design and diagnostic and baseline results of the randomized, phase III ProtecT trial that have just been reported in The Lancet Oncology. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Results of repeat biopsies under electronically tracked, MRI/TRUS fusion guidance

Dr. Leonard Marks and colleagues at the University of California, Los Angeles were among the earliest groups to start to use and publish data on MRI/TRUS fusion biopsies of the prostate. They have now reported some early data on repeat biopsies using such methodology in men on active surveillance. … READ MORE …

The “right” to investigational drug therapy “to save your life”

This November, voters in Arizona will get to determine whether, in their opinions, terminally ill patients should be entitled to have unfettered access to drugs that are in early-stage development but haven’t been approved by the U.S. Food and Drug Administration (FDA). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers